Table 3.
Patients’ Evaluation for Symptoms and Quality of Life Scores in Control Group
| Control Group Patients with OAB Symptoms | Symptom Score (Mean) ± SD | QoL Score (Mean) ± SD |
|---|---|---|
| Before | 12.45 ± 1.23 | 11.61 ± 1.17 |
| After | 12.76 ± 1.37 | 12.05 ± 1.31 |
| P value | >0.05 | >0.05 |
Abbreviations: SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2; COVID-19, Coronavirus Disease 2019; PACS, Post-Acute COVID-19 Syndrome; LUTS, Lower Urinary Tract Symptoms; OAB, Overactive Bladder; CAC, COVID-19 Associated Cystitis; MMSE, Mini-Mental State Examination; AUA OAB tool, AUA Urology Care Foundation Overactive Bladder Assessment Tool; QoL, Quality of Life; ACE2, Angiotensin-Converting Enzyme 2; TSPRSS2, Transmembrane Serine Protease 2.